Outlook Therapeutics (OTLK) announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration to discuss the complete response letter dated August 27, 2025 regarding the biologics license application resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. In the FDA’s recently issued CRL, although the Agency acknowledged the NORSE TWO pivotal trial met its safety and efficacy endpoints, it recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010. The requested Type A meeting seeks to clarify the details of the confirmatory evidence required by the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Marvell downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Hold Rating for Outlook Therapeutics Amid FDA Setbacks and Financial Challenges
- Outlook Therapeutics downgraded to Neutral yesterday at Guggenheim after CRL
- Outlook Therapeutics downgraded at H.C. Wainwright
- Outlook CRL ‘a significant setback,’ doesn’t mean end for Lytenava, says Chardan